You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 284 No. 11, September 20, 2000 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Correction
 This Article
 •PDF of this Correction
 •Original article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Incorrect Wording and Data Presentation and Omitted Acknowledgment

JAMA. 2000;284:1384.

In the Original Contribution entitled "Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial" published in the April 5, 2000, issue of THE JOURNAL (2000;283:1695-1702), incorrect wording and incorrect data presentation were printed. On page 1695, in the "Results" section of the Abstract, the sentence that read "28.1% achieved a glycosylated hemoglobin of less than 7%" should have read "7% or less." On page 1698, the last sentence in the "Glycemic Control" section should have read "Nine patients (7.9%) in the control group, 25 (21.6%) in the 4-mg/d, and 33 (30.0%) in the 8-mg/d rosiglitazone groups achieved FPG concentrations of less than 7.8 mmol/L (140 mg/dL)." On page 1699 in the "Other Metabolic Effects" section, in the penultimate paragraph, which reports triglyceride findings, the phrase that read "in the rosiglitazone groups, the median baseline triglyceride value increased. . . by 0.07 mmol/L (6 mg/dL) from 1.34-mmol/L (119 mg/dL) in 55 patients taking 8-mg/d," should have read "decreased by 0.72 mmol/L (64 mg/dL) from 9.16 mmol/L (280 mg/dL) in 37 patients taking 8 mg/d." The last sentence of the penultimate paragraph of the "Other Metabolic Effects" section was repeated from the prior paragraph and should be deleted. In Table 2, the "Total cholesterol–HDL ratio" section should not have been converted to mmol/L. To calculate the proper ratio, divide the values in that section by 0.0259. In the footnote of Table 2, the cholesterol conversion factor should have read "0.0259." On page 1701 in the "Comment" section in the third column, the line that read "Among patients in the 8-mg/d rosiglitazone group. . . there was a significant statistical decrease observed (6.4-mg/dL)" should have read "(64 mg/dL)." In addition, Sylvia K. Chai, PhD, should have been included in the acknowledgment for her significant contributions to the preparation and review of the article.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.